Tag: dmetrix

New Company Ready to Heat Up Slow Digital Pathology Market

By Robert Michel, from the Volume XXII NO. 11 - August 3, 2015 issue

CEO SUMMARY: There’s a new competitor in the digital pathology marketplace with ambitious plans to deliver a fully-integrated pathologist workflow solution. Inspirata, Inc., of Tampa, Florida, made its debut in March at an international pathology conference. In this exclusive interview, Inspirata Chairman and CEO Satish K. Sanan explains his company’s strategic vision for digital pathology, along with the details of how Inspirata intends to overcome digital pathology’s return-on-investment challenge.

View Article

DMetrix, Bio-Reference Labs, US Clinical Labs, Vidalia Laboratory Services

By Robert Michel, from the Volume XVIII No. 9 - July 05, 2011 issue

DMETRIX PREPARES TO INTRODUCE CHEAPER PATHOLOGY SCANNER
PATHOLOGISTS MAY SOON BE ABLE TO PURCHASE a smaller and less expensive digital scanning system that fits on a microscope. DMetrix, Inc., of Tucson, Arizona, is working to downsize its flagship digital pathology imaging system.

Pixuan “Joe” Zhou, Ph.D, is President of DMetrix. He recently told a reporter for the

View Article

iTunes Business Model For Digital Path Scans

By Robert Michel, from the Volume XV No. 13 - September 29, 2008 issue

CEO SUMMARY: If BioImagene’s CEO is to be believed, the company is ready to deliver a digital pathology system that is robust and affordable, even in settings with just two or three pathologists. One key to the BioImagene strategy is “per scan” pricing that avoids the need for upfront capital to acquire its system. Confident

View Article

Is Digital Path Imaging Ready for Prime Time?

By Robert Michel, from the Volume XV No. 9 - July 7, 2008 issue

CEO SUMMARY: Digital pathology imaging systems are finding uses in all phases of drug discovery (discovery, pre-clinical, clinical trials), as well as education, research, and clinical. One hurdle to widespread adoption of fully digitized, whole-slide pathology imaging systems is FDA clearance that allows the use of this technology for primary diagnosis. Executives at two of

View Article

Volume XXVI No. 2 – February 4, 2019

NOW THAT MOST HOSPITALS ARE INCLUDED as applicable laboratories that must report their PAMA private payer lab test price data to the Centers for Medicare and Medicaid Services, managers of those labs will benefit from the incisive analysis in this issue of the lessons learned during the 2017 PAMA reporting cycle. THE DARK REPORT further offers recommendations on how labs can do a better job of gathering and reporting their own data to CMS. Also, TDR delivers an exclusive analysis of why the Government Accounting Office's assertion that CMS will be paying billions more for Part B clinical lab tests is simply wrong.

See the full table of contents

Tag: dmetrix

Enter Your Login Credentials